These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Health risks after cessation of postmenopausal hormone therapy. Pines A; Sturdee D; Birkhäuser M; Climacteric; 2008 Jun; 11(3):179-80. PubMed ID: 18568782 [No Abstract] [Full Text] [Related]
29. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Genazzani AR; Gadducci A; Gambacciani M Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941 [TBL] [Abstract][Full Text] [Related]
30. Recent studies bring risks, benefits of hormone replacement therapy under scrutiny. Friedrich MJ J Natl Cancer Inst; 2001 Sep; 93(17):1287-8. PubMed ID: 11535698 [No Abstract] [Full Text] [Related]
31. Breast cancer and hormonal supplements in postmenopausal women. Benefits probably outweight risks. Viniker DA BMJ; 1995 Dec; 311(7018):1504-5. PubMed ID: 8520362 [No Abstract] [Full Text] [Related]
32. Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk. Rebbeck TR; Troxel AB; Shatalova EG; Blanchard R; Norman S; Bunin G; Demichele A; Schinnar R; Berlin JA; Strom BL Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1318-20. PubMed ID: 17548708 [No Abstract] [Full Text] [Related]
33. Long-term postmenopausal hormone therapy and endometrial cancer risk: a study by Doherty et al. Odem RR; Moniz MH; Allsworth JE; Bleckman CR; Omicioli VA; Lawrence LT; Thaker PH Am J Obstet Gynecol; 2007 Aug; 197(2):213-4; discussion e1-5. PubMed ID: 17689656 [No Abstract] [Full Text] [Related]
34. [Postmenopausal hormone therapy--an update. Benefit versus risk--important to identify women with increased breast cancer risk]. von Schoultz B Lakartidningen; 2009 Aug 19-25; 106(34):2041-2. PubMed ID: 19769143 [No Abstract] [Full Text] [Related]
35. Where are we with postmenopausal hormone therapy in 2005? Lam PM; Chung TK; Haines C Gynecol Endocrinol; 2005 Nov; 21(5):248-56. PubMed ID: 16373243 [TBL] [Abstract][Full Text] [Related]
36. [Hormone replacement therapy and breast cancer--any news?]. Holli K Duodecim; 1999; 115(2):101-2. PubMed ID: 11830839 [No Abstract] [Full Text] [Related]
37. Hormone replacement therapy and female malignancy: what has the Million Women Study added to our knowledge? Marsden J J Fam Plann Reprod Health Care; 2007 Oct; 33(4):237-43. PubMed ID: 17925102 [No Abstract] [Full Text] [Related]
39. Postmenopausal hormone replacement therapy and major clinical outcomes: a focus on cardiovascular disease, osteoporosis, dementia, and breast and endometrial neoplasia. Dick SE; DeWitt DE; Anawalt BD Am J Manag Care; 2002 Jan; 8(1):95-104; quiz 105-6. PubMed ID: 11814176 [TBL] [Abstract][Full Text] [Related]
40. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? Soerjomataram I; Coebergh JW; Louwman MW; Visser O; van Leeuwen FE J Clin Oncol; 2007 Nov; 25(31):5038-9; author reply 5039-40. PubMed ID: 17971608 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]